Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pingyangmycin Interstitial Injection for Port-Wine Stain-Associated Facial/Labial Hypertrophy
ChiCTR2600128083Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jul 2026
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in hemifacial hypertrophy and port-wine stain comparing Pingyangmycin Injection Group with Placebo Control Group (2 arms). Primary endpoint: Degree of reduction in hypertrophic lesion volume. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
pingyangmycin
03
Conditions
hemifacial hypertrophyport-wine stain
Beyond the preview
Go deeper on ChiCTR2600128083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600128083.